A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD
| Autor: | Kenechukwu Chudy-Onwugaje, Francis A. Farraye, Raymond K. Cross, Kaci E. Christian |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Moderate to severe medicine.medical_specialty Phases of clinical research Disease Inflammatory bowel disease Corrections 03 medical and health sciences 0302 clinical medicine Gastrointestinal Agents Immunology and Allergy Medicine Animals Humans Intensive care medicine Adverse effect Crohn's disease business.industry Tumor Necrosis Factor-alpha Gastroenterology Antibodies Monoclonal State of the art review medicine.disease Inflammatory Bowel Diseases Ulcerative colitis digestive system diseases 030104 developmental biology 030211 gastroenterology & hepatology business |
| Zdroj: | Inflammatory bowel diseases. 25(5) |
| ISSN: | 1536-4844 |
| Popis: | Over the last 2 decades, novel therapies targeting several immune pathways have been developed for the treatment of patients with inflammatory bowel disease (IBD). Although anti–tumor necrosis factor (anti-TNF) agents remain the firstline treatment for moderate to severe Crohn’s disease and ulcerative colitis, many patients will require alternative agents, due to nonresponse, loss of response, or intolerance of anti-TNFs. Furthermore, patients may request newer therapies due to improved safety profiles or improved administration (ie, less frequent injection, oral therapy). This review will focus on new and emerging therapies for the treatment of IBD, with a special focus on their adverse effects. Although many of the agents included in this paper have been approved for use in IBD, a few are still in development but have been shown to be effective in phase II clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|